Sign Out
Hypersensitivity to doxorubicin or to any of the excipients, other anthracyclines or anthracenediones.
Intravenous (IV) use: persistent myelosuppression; severe hepatic impairment; severe myocardial insufficiency; recent myocardial infarction; severe arrhythmias; previous treatment with maximum cumulative doses of doxorubicin,
daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones.
Continue with Google